Identification of bradycardia following remdesivir administration through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project

Authors

Jason M Devgun, Washington University School of Medicine in St. Louis
Rongmei Zhang, Food and Drug Administration
Jeffrey Brent, University of Colorado
Paul Wax, University of Texas Southwestern Medical Center at Dallas
Keith Burkhart, Food and Drug Administration
Alison Meyn, American College of Medical Toxicology
Sharan Campleman, American College of Medical Toxicology
Stephanie Abston, American College of Medical Toxicology
Kim Aldy, University of Texas Southwestern Medical Center at Dallas
Toxicology Investigators Consortium FACT Study Group

Journal

JAMA Network Open

Publication Date

2-1-2023

Volume

6

Issue

2

First Page

e2255815

Document Type

Open Access Publication

DOI

10.1001/jamanetworkopen.2022.55815

Rights and Permissions

Devgun JM, Zhang R, Brent J, et al. Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. JAMA Netw Open. 2023;6(2):e2255815. doi:10.1001/jamanetworkopen.2022.55815. This is an open access article distributed under the terms of the CC-BY License. © 2023 Devgun JM et al. JAMA Network Open.

Recommended Citation

Devgun, Jason M; Zhang, Rongmei; Brent, Jeffrey; Wax, Paul; Burkhart, Keith; Meyn, Alison; Campleman, Sharan; Abston, Stephanie; Aldy, Kim; and Toxicology Investigators Consortium FACT Study Group, "Identification of bradycardia following remdesivir administration through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project." JAMA Network Open. 6, 2. e2255815 (2023).
https://digitalcommons.wustl.edu/oa_4/1426

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.